Physician profile
Robert Douglas Grigg
NPI 1407371941
$5,578.52
in general payments reported to CMS, 2019-2025
26 companies · $982 in 2025
The $982 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,133 · 2022: $733 · 2023: $1,346 · 2024: $1,385 · 2025: $982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,681 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,680.64 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,245.67 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $771.60 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $474.59 | 2021-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $433.53 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $389.41 | 2023-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $223.29 | 2021-2024 | |
| Pfizer INC. | $196.76 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $195.93 | 2023-2024 | Quviviq |
| Daiichi Sankyo INC. | $195.30 | 2023-2025 | Injectafer |
| Lilly USA, LLC | $189.37 | 2022-2024 | Jardiance, Emgality, Zepbound |
| Glaxosmithkline, LLC. | $184.82 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $169.90 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $167.39 | 2022-2025 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Exact Sciences Corporation | $141.68 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.15 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $136.20 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Antares Pharma, INC. | $61.29 | 2024 | Xyosted |
| Mylan Specialty L.P. | $42.30 | 2023-2024 | Yupelri |
| Sanofi Pasteur INC. | $39.50 | 2023-2025 | |
| Bausch Health US, LLC | $35.78 | 2022-2023 | Aplenzin |
| Phathom Pharmaceuticals, INC. | $33.40 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $28.52 | 2023 | Gattex |
| Tarsus Pharmaceuticals, INC. | $25.65 | 2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $19.48 | 2025 | Infuse |
| Sk Life Science, INC. | $18.66 | 2022 | |
| Viatris Specialty LLC | $18.35 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Grigg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.